ANDA 88802, held by Hikma. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 88802 (Lidocaine Viscous), held by Hikma, was first approved by FDA on Apr 26, 1985, with 16 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 26, 1985 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Viscous2% · solution;oral | Lidocaine Hydrochloride | Rx |
| Nov 2, 2018 | Supplement 25Labeling · Standard review | Approved | None posted |
| Nov 17, 2014 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jun 30, 2008 | Supplement 20Labeling | Approved | None posted |
| Feb 14, 2002 | Supplement 17Manufacturing | Approved | None posted |
| Jun 15, 1998 | Supplement 16Manufacturing | Approved | None posted |
| Aug 28, 1996 | Supplement 14Manufacturing | Approved | None posted |
| Mar 29, 1996 | Supplement 13Labeling | Approved | None posted |
| Jun 30, 1995 | Supplement 12Manufacturing | Approved | None posted |
| Jun 1, 1994 | Supplement 11Manufacturing | Approved | None posted |
| Jun 12, 1991 | Supplement 10Labeling | Approved | None posted |
| Mar 21, 1991 | Supplement 9Labeling | Approved | None posted |
| Nov 16, 1990 | Supplement 8Labeling | Approved | None posted |
| Oct 11, 1988 | Supplement 6Manufacturing | Approved | None posted |
| Oct 27, 1987 | Supplement 4Manufacturing | Approved | None posted |
| Oct 27, 1987 | Supplement 3Manufacturing | Approved | None posted |
| Apr 17, 1986 | Supplement 2Manufacturing | Approved | None posted |
| Apr 26, 1985 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters